Long-term Pharmacological Activation of PPARγDoes not Prevent Left Ventricular Remodeling in Dogs with Advanced Heart Failure

By Suzuki George   Khanal Sanjaya   Rastogi Sharad   Morita Hideaki   Mishima Takayuki   Anagnostopoulos Petros   Nass Omar   Sharov Victor   Tanhehco Elaine   Goldstein Sidney   Sabbah Hani  

Cardiovascular Drugs and Therapy, Vol. 21, Iss. 1, 2007-02 ,pp. : 29-36

Springer Publishing Company

Access to resources Recommend Favorite

The Protective Effects of Angiotensin II Blockade with Olmesartan Medoxomil on Resistance Vessel Remodeling (The VIOS study): Rationale and Baseline Characteristics

By Smith Ronald D.  

American Journal of Cardiovascular Drugs, Vol. 6, Iss. 5, 2006-01 ,pp. : 335-342

Adis International

Access to resources Recommend Favorite

Functional interactions of L-162,313 with angiotensin II receptor subtypes and mutants

By Vianello B.   Clauser E.   Corvol P.   Monnot C.  

European Journal of Pharmacology, Vol. 347, Iss. 1, 1998-04 ,pp. : 113-118

Elsevier

Access to resources Recommend Favorite

Functional Relevance of Biased Signaling at the Angiotensin II Type 1 Receptor

By  

Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol. 11, Iss. 2, 2011-06 ,pp. : 99-111

Bentham Science Publishers

Access to resources Recommend Favorite

Recent Progress in Molecular Mechanisms of Angiotensin II Type 1 and 2 Receptors

By  

Current Pharmaceutical Design, Vol. 19, Iss. 17, 2013-05 ,pp. : 2981-2987

Bentham Science Publishers

Access to resources Recommend Favorite